Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70121-1237-01 70121-1237 AZACITIDINE AZACITIDINE 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 9, 2022 In Use
00310-1350-30 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 13, 2015 In Use
00310-1350-95 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral March 15, 2019 In Use
50419-0171-00 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sept. 27, 2012 In Use
50419-0171-01 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sept. 27, 2012 In Use
50419-0171-03 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sept. 27, 2012 In Use
50419-0171-04 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sept. 27, 2012 In Use
50419-0171-06 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral May 1, 2021 In Use
00078-0860-01 00078-0860 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00310-1349-30 00310-1349 Osimertinib Tagrisso 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 13, 2015 In Use
62856-0708-05 62856-0708 Lenvatinib Lenvima 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral May 13, 2016 In Use
62856-0708-30 62856-0708 Lenvatinib Lenvima 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral May 13, 2016 In Use
62856-0710-05 62856-0710 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0710-30 62856-0710 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0720-05 62856-0720 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
62856-0720-30 62856-0720 Lenvatinib Lenvima 10.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET Oral Feb. 13, 2015 In Use
63323-0172-05 63323-0172 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2009 Oct. 31, 2012 In Use
63323-0172-15 63323-0172 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2009 Jan. 31, 2014 In Use
63323-0172-45 63323-0172 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2009 Aug. 31, 2017 In Use
63323-0172-60 63323-0172 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 11, 2009 In Use
71335-1772-01 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-02 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-03 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-04 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-05 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-06 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Jan. 21, 2021 In Use
71335-1772-07 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
71335-1772-08 71335-1772 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 29, 2021 In Use
67457-0662-05 67457-0662 TOPOTECAN TOPOTECAN 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous April 9, 2018 Feb. 28, 2022 No Longer Used
70860-0201-10 70860-0201 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous March 15, 2017 In Use
70860-0201-20 70860-0201 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous March 15, 2017 In Use
61703-0350-09 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous Sept. 25, 2014 In Use
61703-0350-10 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous Sept. 25, 2014 In Use
61703-0350-37 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous July 27, 2005 In Use
61703-0350-38 61703-0350 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intravenous, Subcutaneous July 27, 2005 In Use
61703-0408-22 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Feb. 26, 2001 Nov. 2, 2011 In Use
61703-0408-25 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Nov. 11, 2013 In Use
61703-0408-41 61703-0408 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous Feb. 26, 2001 In Use
16714-0727-01 16714-0727 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
16714-0728-01 16714-0728 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
68001-0370-27 68001-0370 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68001-0371-32 68001-0371 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68001-0372-32 68001-0372 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 23, 2018 March 31, 2022 No Longer Used
68152-0109-00 68152-0109 Melphalan Evomela 50.0 mg/10mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 31, 2016 March 31, 2022 No Longer Used
43598-0143-62 43598-0143 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous April 20, 2022 In Use
24979-0710-51 24979-0710 Paclitaxel Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous April 1, 2022 In Use
60505-6230-04 60505-6230 Paclitaxel Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous April 1, 2022 In Use
55150-0355-01 55150-0355 IRINOTECAN HYDROCHLORIDE IRINOTECAN HYDROCHLORIDE 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous April 11, 2022 In Use
71288-0169-25 71288-0169 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb. 28, 2022 In Use
68083-0535-10 68083-0535 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous April 22, 2022 In Use

Found 10,000 results in 4 milliseconds — Export these results